With Revlimid sales down, BMS slashes 2023 revenue projection
BMS has sliced its 2023 sales projection for Revlimid by a whopping $1 billion and cut its overall revenue projection from a 2% increase to a decline.
Admin 27, 2023 11:08pmLilly, BI's Jardiance scores EU nod in chronic kidney disease
After recent label expansions paid off with a sizable sales increase for Jardiance, the drug has added a third use to its European label.
Admin 27, 2023 11:08pmUK probes GLP-1 drugs' potential suicide risks: Reuters
Following in European regulators' footsteps, the U.K. has launched a probe into potential suicide risks for popular diabetes and weight-loss drugs.
Admin 27, 2023 11:08pm